Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
PTX-5001
NCT00023166
May 2001
May 2002
Name | Location |
---|